Efficacy, Safety of Baricitinib plus Remdesivir versus Standard Therapy (Remdesivir) in Patients with Severe COVID-19 Infection in Third Wave of Epidemics in Myanmar: Case Control Study
Journal Title: International Journal Of Medical Science And Clinical Research Studies - Year 2022, Vol 2, Issue 03
Abstract
threat to health around the world as it causes significant morbidity and mortality. SARS-CoV-2 infection induces severe inflammation in lungs and multi-organs; therefore, the Janus kinase (JAK) inhibitor known as baricitinib was proposed as a treatment for COVID-19 because of its anti-inflammatory and potential antiviral effects. It may improve survival in patients with severe Covid-19 infection. The efficacy and safety of Baricitinib therapy in severe COVID-19 infection in Myanmar was not known clearly. Methods: A case control study was conducted in COVID-19 treatment centers in Myanmar- Yangon and Nay Pyi Taw, from June to October 2021. Baricitinib 4 mg daily for 14 days was given to the patients with severe COVID-19 infection as an add on therapy to Standard treatment group (Remdesivir). The primary outcome was survival status; survive or non-survive. The secondary outcome was duration of hospital stay, the requirement for oxygen therapy at Day 7 (improved or not), changes in chest radiograph at Day 14 (improved, same or worse), and changes in inflammatory markers (CPR and LDH). Patient data were stratified by age, sex, body weight, co-morbidities and immune status (immunocompromised or normal immune status). Data were collected by using standardized forms and analysis was done. Results: A total of 64 patients with severe COVID-19 infection were enrolled. Base line characteristics in both groups, Baricitinib group (n =32) and Standard treatment group (n = 32), were comparable. Nearly 53% of patients in Baricitinib group and 59% of patients in Standard treatment group survived; however, mean duration of hospital stay was shorter in Baricitinib group (15.53 ± 6.83 days versus 22.25 ± 11.17 days; p < 0.001). Improvement in oxygen supplementation, radiological changes and changes in inflammatory markers were not different in both groups. Minor side effects like giddiness, appetite loss and insomnia were noted in Baricitinib group. Conclusions: In treating patients with severe COVID-19 infection, the survival rate was not different between Baricitinib group (Baricitinib plus Remdesivir) and Standard treatment group (Remdesivir). In survivors, those in Baricitinib group had shorter duration of hospital stays; quick recovery time and accelerating improvement in clinical status
Authors and Affiliations
Khin Phyu Pyar, Sai Aik Hla, Aung Phyoe Kyaw, Nyan Lin Maung, Zar Ni Htet Aung, Thi Han Tun, Min Aung Shan, Yan Lin Aung, Kyaw Zaw Lin, Si Phyo Thu, Thu Htoo Kyaw, Kyaw Zay Ya, Myo Thant Kyaw, Zay Phyo Aung, Than Tun Aung, Aung Thit, Aung Hlaing Win, Myo Min Thu, Thurein Wynn, Han Lin Aung, Lynn Htet Aung, Lay Maung Maung, Ye Min Hein, Moe Tun Zaw, Myo Maung Maung, Myo Min Thant
Keywords
Related Articles
- EP ID EP713626
- DOI 10.47191/ijmscrs/v2-i3-07
- Views 36
- Downloads 0
Risk Factors for Treatment Failure with Oral Antivirals in HCV
Introduction: Chronic hepatitis C virus (HCV) infection is one of the major cause of cirrhosis of liver and leads to significant morbidity and mortality. In past, HCV therapy was limited to subcutaneous peg interferon pl...
Client Satisfaction regarding Drug Dispensing Services in Tertiary Public Hospital during COVID-19 Pandemic
Background:Client satisfaction is the degree of positive feeling that patients or clients having used a service. It indicates also the gap between quality-of-service expectation and the actual exp...
Health Problems of Women Working in Night Shift in India: A Review
Women in India are regarded as one of the country's most valuable resources. Working women of India are characterized by growth and development, but they are vulnerable often by several factors which affect their health...
Large Ostium Secundum ASD Occlusion with Memopart ASD Occluder
Transcatheter occlusion of ASD with device is an effective,alternative to surgical repair : feasible and safe procedure with minimal complication rate and short hospital stay, as well as excellent short and lo...
Hypereosinophilic Syndrome, Erythroderma as Clinical Debut. Case Report and Literature Review
Eosinophilia is a common finding in clinical practice, but when elevated values of eosinophils are found, it constitutes a diagnostic challenge. Hypereosinophilic syndrome is a group of rare disorders defined by persis...